Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

The trial was investigating the use of vagus nerve stimulation (VNS) for inflammatory bowel disease (IBD), an autoimmune ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those ...

A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM ...

ORLANDO -- Longer hospitalization for flares of inflammatory bowel disease (IBD) was linked to greater risk of subsequent ...

We welcome the decision by the UK Joint Committee on Vaccination and Immunisation (JCVI) to broaden the eligibility for the vaccination programme for the Shingrix recombinant herpes zoster vaccine ...

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.

Ira Daniel Breite, MD, is a board-certified internist and gastroenterologist. He is an associate professor at the Icahn ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...

Developed by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.

ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...

A complex, chronic, and debilitating condition, inflammatory bowel disease (IBD) affects roughly 3 million Americans, including those with Crohn's disease and ulcerative colitis.